287 related articles for article (PubMed ID: 28385603)
1. Research progress in advanced melanoma.
Luo C; Shen J
Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
[TBL] [Abstract][Full Text] [Related]
2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
3. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies for melanoma.
Katipamula R; Markovic SN
Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis in melanoma: an update with a focus on current targeted therapies.
Jour G; Ivan D; Aung PP
J Clin Pathol; 2016 Jun; 69(6):472-83. PubMed ID: 26865640
[TBL] [Abstract][Full Text] [Related]
6. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
[TBL] [Abstract][Full Text] [Related]
7. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
8. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapies for melanoma brain metastases: which drug for whom and when?
Ramanujam S; Schadendorf D; Long GV
Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in esophageal cancer.
Zhang L; Ma J; Han Y; Liu J; Zhou W; Hong L; Fan D
Expert Rev Gastroenterol Hepatol; 2016; 10(5):595-604. PubMed ID: 26895097
[TBL] [Abstract][Full Text] [Related]
11. Choice of first-line therapy in metastatic melanoma.
Gibney GT; Atkins MB
Cancer; 2019 Mar; 125(5):666-669. PubMed ID: 30695110
[No Abstract] [Full Text] [Related]
12. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
13. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
14. The systemic treatment of advanced cutaneous melanoma.
Logan TF
Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
[No Abstract] [Full Text] [Related]
15. Melanoma vaccines: possible progress after years of frustration?
Schmidt C
J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
[No Abstract] [Full Text] [Related]
16. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
17. Treating metastatic melanoma in 2014: what just happened and what is next?
Chapman PB
Am Soc Clin Oncol Educ Book; 2014; ():16-9. PubMed ID: 24857055
[TBL] [Abstract][Full Text] [Related]
18. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
Strickland LR; Pal HC; Elmets CA; Afaq F
Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
[TBL] [Abstract][Full Text] [Related]
19. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
20. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
